PharmaJet Announces Appointment of Nathalie Landry as Chief Scientific Officer
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet,® a company engineering Precision Delivery Systems™ that may overcome the challenges of vaccines and pharmaceuticals delivery today announced that Nathalie Landry, has been appointed Chief Scientific Officer.
Chris Cappello, President, and CEO, PharmaJet said, “We are excited to welcome Ms. Landry to PharmaJet. With 75 development partners and over 100 clinical studies in progress, our pipeline of projects has grown significantly. Ms. Landry’s vast experience in vaccine development and cross-functional management will provide strategic leadership to ensure the company’s clinical and scientific programs align with our global commercial expansion.”
Ms. Landry has over 30 years of experience in the successful development of a new technology platform as well as innovative vaccines and pharmaceuticals from proof-of-concept to late-stage clinical trials and regulatory approval. Prior to joining PharmaJet, she was Executive Vice President, Scientific and Medical Affairs at Medicago, an international leader in plant-based technology producing vaccines and therapeutics, where she led a group of 125+ professionals responsible for all R&D activities, analytical and process development, preclinical and clinical development, medical affairs, and pharmacovigilance activities. She directed the development of a quadrivalent seasonal influenza vaccine as well as an approved COVID-19 vaccine including supporting Phase 3, commercial production and regulatory approval. She has published over 25 articles in major international scientific journals, two book chapters and is co-inventor on 8 patent families. Ms. Landry holds a Master of Microbiology-Immunology and an MBA from the Université Laval.
Ms. Landry added, “I am thrilled to join the talented team at PharmaJet and to work with its partners to further expand the portfolio of vaccines and therapeutics delivered by these innovative precision delivery systems.”
The PharmaJet vision is to enable greater access to life-saving vaccines and pharmaceuticals globally. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information visit https://pharmajet.com. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005014/en/
1-888-900-4321 Option 3
View this news release online at: